Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

  • Side effect of GilenyaSubscription

    Progressive multifocal leukoencephalopathy has been added as an adverse event of unknown frequency to the summary of product characteristics for Gilenya (fingolimod; Novartis).

  • Side effects of ZytigaSubscription

    Increased alanine aminotransferase and increased aspartate aminotransferase are now listed as common adverse reactions in the summary of product characteristics for Zytiga (abiraterone; Janssen-Cilag). Hepatitis fulminant and acute hepatic failure have been added as rare adverse reactions.

Other product updates

  • NICE does not recommend ibrutinibSubscription

    The National Institute for Health and Care Excellence (NICE) has published draft guidance that does not recommend ibrutinib within its marketing authorisation for treating chronic lymphocytic leukaemia. A consultation on the guidance will be available on the NICE website until 23 March 2016.

Other notifications